Ketamine

GPTKB entity

Statements (65)
Predicate Object
gptkbp:instanceOf gptkb:drug
dissociative anesthetic
gptkbp:ATCCode gptkb:N01AX03
gptkbp:black_box_warning no
gptkbp:can_cause_bladder_toxicity yes
gptkbp:can_cause_cognitive_impairment yes
gptkbp:can_cause_dependence yes
gptkbp:CASNumber 6740-88-1
gptkbp:chemicalFormula C13H16ClNO
gptkbp:discoveredBy gptkb:Calvin_Stevens
gptkbp:discoveredIn 1962
gptkbp:eliminationHalfLife 2.5–3 hours
gptkbp:excretion gptkb:kidney
gptkbp:first_approved_for_medical_use 1970
gptkbp:has_antidepressant_effect yes
gptkbp:has_rapid_onset_of_action yes
gptkbp:hasEnantiomer gptkb:arketamine
gptkb:esketamine
gptkbp:hasStreet gptkb:Kit_Kat
gptkb:Special_K
K
https://www.w3.org/2000/01/rdf-schema#label Ketamine
gptkbp:IUPACName (RS)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
gptkbp:KEGGID D08014
gptkbp:legalStatus gptkb:Class_B_(UK)
gptkb:Schedule_III_(US)
Schedule I (Canada)
gptkbp:mechanismOfAction NMDA receptor antagonist
dopamine reuptake inhibitor
opioid receptor agonist (weak)
gptkbp:meltingPoint 258–261 °C (hydrochloride salt)
gptkbp:MeSH_ID D007662
gptkbp:metabolism liver
gptkbp:molecularWeight 237.725 g/mol
gptkbp:overdoseSymptoms coma
seizures
respiratory depression
gptkbp:pregnancyCategory C (US)
gptkbp:PubChem_CID gptkb:CHEMBL402
3821
DB01221
gptkbp:relatedTo gptkb:methoxetamine
gptkb:phencyclidine
gptkbp:routeOfAdministration oral
intramuscular
intravenous
intranasal
gptkbp:sideEffect nausea
dissociation
hallucinations
agitation
elevated blood pressure
gptkbp:solubility soluble in water (hydrochloride salt)
gptkbp:UNII 690G0D6V8H
gptkbp:used_in_veterinary_medicine yes
gptkbp:used_recreationally yes
gptkbp:usedFor pain management
treatment-resistant depression
anesthesia
status epilepticus
sedation
gptkbp:WHOModelListOfEssentialMedicines yes
gptkbp:bfsParent gptkb:Schedule_III
gptkb:Princess_Goes_to_the_Butterfly_Museum
gptkbp:bfsLayer 6